Senator Hatch, before pressuring Colombia over cancer drug compulsory license, wanted one for Napster
(More on Colombia here: /colombia)
Continue Reading
Fundación Karisma at WIPO SCCR32 on broadcast treaty
Good afternoon, and thank you very much, sir.
I wanted to refer to the rights to be granted in this proposed treaty and I would like to give you an example of something that has recently happened in Colombia and how sometimes the retransmission rights can be abused.
2016: Dedalus Pharma, LLC, KEI comments on NIH proposal for exclusive licenses on CARs to treat cancer
(More on government funded inventions here. Other KEI comments on NIH licenses are found here.) On April 22nd, 2016 the NIH posted a notice on the Federal Register stating it is contemplating the grant of an exclusive license to Dedalus… Continue Reading
KEI Comments to DHHS on WHA 69 re CEWG, Nocommunicable Diseases
Today the Department of Health and Human Services held their annual WHA listening session. This year HHS sent an email the day prior announcing that the usual 3 minute allotment would be cut in half to 90 seconds. This decision caused several NGOs to not attend.
Xtandi patient on Medicare — with supplement — pays $441.97 per month
Astellas has claimed that patients taking Xtandi face very small co-payments. One patient living in Arizona contacted KEI with proof that Astellas’ claims just aren’t true. The patient, who is on Medicare, provided a copy of a summary of his expenses for the first quarter of of 2016.
His monthly patient co-payment is $441.97 a month.
2016: KEI objections to NIH licenses to Vital Spark, Kalytera Therapeutics, CB1 receptor mediating compounds
(More on government funded inventions here. Other KEI comments on NIH licenses are found here.) May 4, 2016 Betty Tong, Ph.D. Senior Licensing and Patenting Manager Technology Advancement Office National Institute of Diabetes and Digestive and Kidney Diseases 12A South… Continue Reading
2016: NIH FOIA office withholds all records related to exclusive license on HER2+ breast cancer treatment technology
Other KEI comments on NIH licenses are found here: /nih-licenses
In response to a February request under the Freedom of Information Act (FOIA) for documents related to the grant of an exclusive patent license on a HER2+ breast cancer treatment technology, the National Institutes of Health (NIH) withheld in full all responsive records.
WHO CEWG 2016: Statement of Health Action International, Knowledge Ecology International and STOPAIDS
On Monday, 2 May 2016, the World Health Organization (WHO) convened the 2016 open-ended member states meeting of the Consultative Expert Working Group on Research and Development: Financing and Coordination (CEWG). The 2016 CEWG is chaired by Bhanu Pratap Sharma, Secretary, Ministry of Health and Family Welfare, Government of India. The Vice-Chair is Tania Dussey- Cavassini, Vice-Director General, Ambassador for Global Health, Federal Office of Public Health, Switzerland.
Rep. Lloyd Doggett keynote address at CAP drug pricing event highlights Xtandi, federal funding of pharmaceutical R&D
On April 26, 2016, Congressman Lloyd Doggett (D-Texas) delivered the keynote address at a panel discussion on drug pricing at the Center for American Progress, where he addressed the Federal government’s role in subsidizing drug development, ensuring affordable access at reasonable prices for U.S. citizens, industry practices related to monopoly pricing, and legislative solutions to promote rational and affordable drug prices.
China: as PCT patent filings increase, GDP growth has decreased
The number of patents filed by China has accelerated over the last 15 years. According to WIPO, China represented just 1 percent of the fillings with the PCT in 2000. By 2015, China’s share of PCT filing was 13.7 percent. We were interested to see how this increase in patent fillings related to China’s growth in GDP.